ENTRY       D08923                      Drug
NAME        Fesoterodine fumarate (JAN/USAN);
            Toviaz (TN)
PRODUCT     TOVIAZ (Pfizer Laboratories Div Pfizer)
            TOVIAZ (U.S. Pharmaceuticals)
  GENERIC   FESOTERODINE FUMARATE (ANI Pharmaceuticals)
            FESOTERODINE FUMARATE (Alembic Pharmaceuticals Limited)
            FESOTERODINE FUMARATE (Alembic Pharmaceuticals)
            FESOTERODINE FUMARATE (Amneal Pharmaceuticals LLC)
            FESOTERODINE FUMARATE (Ascend Laboratories)
            FESOTERODINE FUMARATE (Aurobindo Pharma Limited)
            FESOTERODINE FUMARATE (Dr.Reddy's Laboratories Inc.,)
            FESOTERODINE FUMARATE (Golden State Medical Supply)
            FESOTERODINE FUMARATE (Zydus Lifesciences Limited)
            FESOTERODINE FUMARATE (Zydus Pharmaceuticals USA)
FORMULA     C26H37NO3. C4H4O4
EXACT_MASS  527.2883
MOL_WEIGHT  527.649
CLASS       Neuropsychiatric agent
             DG01491  Muscarinic cholinergic receptor antagonist
            Metabolizing enzyme substrate
             DG01644  CYP2D6 substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
REMARK      Therapeutic category: 2590
            ATC code: G04BD11
            Chemical structure group: DG00483
            Product (DG00483): D08923<JP/US>
EFFICACY    Overactive bladder agent, Muscarinic acetylcholine receptor antagonist
COMMENT     Treatment of overactive bladder
TARGET      CHRM3 [HSA:1131] [KO:K04131]
            CHRM2 [HSA:1129] [KO:K04130]
  PATHWAY   hsa04020(1129+1131)  Calcium signaling pathway
            hsa04080(1129+1131)  Neuroactive ligand-receptor interaction
            hsa04725(1129+1131)  Cholinergic synapse
METABOLISM  Enzyme: CYP2D6 [HSA:1565], CYP3A4 [HSA:1576]
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             G GENITO URINARY SYSTEM AND SEX HORMONES
              G04 UROLOGICALS
               G04B UROLOGICALS
                G04BD Drugs for urinary frequency and incontinence
                 G04BD11 Fesoterodine
                  D08923  Fesoterodine fumarate (JAN/USAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Genitourinary Agents
              Antispasmodics, Urinary
               Cholinergic Muscarinic Antagonists
                Fesoterodine
                 D08923  Fesoterodine fumarate (JAN/USAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             2  Agents affecting individual organs
              25  Urogenital and anal organ agents
               259  Miscellaneous
                2590  Miscellaneous
                 D08923  Fesoterodine fumarate (JAN/USAN)
            Drug groups [BR:br08330]
             Neuropsychiatric agent
              DG01491  Muscarinic cholinergic receptor antagonist
               DG00483  Fesoterodine
                D08923  Fesoterodine fumarate
             Metabolizing enzyme substrate
              DG01644  CYP2D6 substrate
               DG00483  Fesoterodine
                D08923  Fesoterodine fumarate
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                DG00483  Fesoterodine
                 D08923  Fesoterodine fumarate
            Target-based classification of drugs [BR:br08310]
             G Protein-coupled receptors
              Rhodopsin family
               Acetylcholine (muscarinic)
                CHRM2
                 D08923  Fesoterodine fumarate (JAN/USAN) &lt;JP/US&gt;
                CHRM3
                 D08923  Fesoterodine fumarate (JAN/USAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D08923
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D08923
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D08923
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D08923
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D08923
            Pharmacogenomic biomarkers [br08341.html]
             Polymorphisms and mutations affecting drug response
              D08923
            Drug groups [BR:br08330]
             Neuropsychiatric agent
              DG01491  Muscarinic cholinergic receptor antagonist
               DG00483  Fesoterodine
             Metabolizing enzyme substrate
              DG01644  CYP2D6 substrate
               DG00483  Fesoterodine
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                DG00483  Fesoterodine
DBLINKS     CAS: 286930-03-8
            PubChem: 96025606
            LigandBox: D08923
ATOM        38
            1   C1c C    15.5400  -14.9800
            2   N1c N    16.7300  -15.6800
            3   C1b C    17.9200  -15.0500
            4   C1b C    19.1100  -15.7500
            5   C1c C    20.4400  -15.0500
            6   C8y C    21.6300  -15.7500
            7   C8x C    22.8200  -15.0500
            8   C8y C    24.0800  -15.7500
            9   C1b C    25.2700  -15.1200
            10  C1a C    15.5400  -13.5800
            11  C1c C    16.7300  -17.1500
            12  C1a C    15.4700  -17.7800
            13  C1a C    17.9900  -17.7800
            14  C8y C    21.6300  -17.1500
            15  C8x C    24.0800  -17.1500
            16  C8x C    22.8200  -17.8500
            17  O7a O    20.4400  -17.7800
            18  O1a O    26.4600  -15.8200
            19  C1a C    14.3500  -15.6800
            20  C8y C    20.4400  -13.5800
            21  C8x C    21.7000  -12.8800
            22  C8x C    21.7000  -11.4800
            23  C8x C    20.5100  -10.7800
            24  C8x C    19.2500  -11.4100
            25  C8x C    19.2500  -12.8100
            26  C7a C    20.4400  -19.1800
            27  O6a O    21.7000  -19.8100
            28  C1c C    19.2500  -19.8800
            29  C1a C    18.0600  -19.1800
            30  C1a C    19.2500  -21.2800
            31  O6a O    31.5700  -16.7300
            32  C6a C    32.7824  -16.0300
            33  C2b C    33.9949  -16.7300
            34  C2b C    35.2073  -16.0300
            35  C6a C    36.4197  -16.7300
            36  O6a O    37.6322  -16.0300
            37  O6a O    32.7824  -14.6302
            38  O6a O    36.4197  -18.1299
BOND        38
            1     1   2 1
            2     2   3 1
            3     3   4 1
            4     5   4 1
            5     5   6 1
            6     6   7 1
            7     7   8 2
            8     8   9 1
            9     1  10 1
            10    2  11 1
            11   11  12 1
            12   11  13 1
            13    6  14 2
            14    8  15 1
            15   14  16 1
            16   16  15 2
            17   14  17 1
            18    9  18 1
            19    1  19 1
            20    5  20 1 #Down
            21   20  21 2
            22   21  22 1
            23   22  23 2
            24   23  24 1
            25   24  25 2
            26   20  25 1
            27   17  26 1
            28   26  27 2
            29   26  28 1
            30   28  29 1
            31   28  30 1
            32   31  32 1
            33   32  33 1
            34   33  34 2
            35   34  35 1
            36   35  36 1
            37   32  37 2
            38   35  38 2
///
